The USFDA has approved the first interchangeable biosimilar insulin product, which aims to enhance glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and adults with Type 2 diabetes mellitus. The availability of affordable insulin is crucial, and long-acting insulin products, such as insulin glargine, play a significant role in treating type 1 and type 2 diabetes mellitus. Insulin glargine-yfgn is the first interchangeable biosimilar to be approved by the USFDA to treat diabetes.
It is similar to its reference product, insulin glargine. The approval of insulin glargine-yfgn biosimilar is based on evidence, which showed no significant differences with insulin glargine in terms of: Safety and efficacy Clinical trial results Diminished efficacy Insulin glargine-yfgn Available as 10 mL vials and 3 mL prefilled pens To be administered subcutaneously Dosing…
